These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 9419454)

  • 1. Human leukemia-derived dendritic cells: ex-vivo development of specific antileukemic cytotoxicity.
    Choudhury A; Toubert A; Sutaria S; Charron D; Champlin RE; Claxton DF
    Crit Rev Immunol; 1998; 18(1-2):121-31. PubMed ID: 9419454
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clonal heterogeneity of dendritic cells derived from patients with chronic myeloid leukemia and enhancement of their T-cells stimulatory activity by IFN-alpha.
    Wang C; Al-Omar HM; Radvanyi L; Banerjee A; Bouman D; Squire J; Messner HA
    Exp Hematol; 1999 Jul; 27(7):1176-84. PubMed ID: 10390193
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dendritic cells generated from blood precursors of chronic myelogenous leukemia patients carry the Philadelphia translocation and can induce a CML-specific primary cytotoxic T-cell response.
    Eibl B; Ebner S; Duba C; Böck G; Romani N; Erdel M; Gächter A; Niederwieser D; Schuler G
    Genes Chromosomes Cancer; 1997 Nov; 20(3):215-23. PubMed ID: 9365828
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Analysis of a chronic myelogenous leukemia patient vaccinated with leukemic dendritic cells following autologous peripheral blood stem cell transplantation.
    Fujii S; Shimizu K; Fujimoto K; Kiyokawa T; Shimomura T; Kinoshita M; Kawano F
    Jpn J Cancer Res; 1999 Oct; 90(10):1117-29. PubMed ID: 10595741
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Therapeutic potential of leukemia-derived dendritic cells: preclinical and clinical progress.
    Claxton DF; McMannis J; Champlin R; Choudhury A
    Crit Rev Immunol; 2001; 21(1-3):147-55. PubMed ID: 11642601
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chronic myeloid leukemia as an immunological target.
    Lim SH; Coleman S
    Am J Hematol; 1997 Jan; 54(1):61-7. PubMed ID: 8980262
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serum-free culture of dendritic cells from patients with chronic myeloid leukemia in vitro and estimation of their cytotoxicity.
    Zhao W; Xing P; Wei X; Wang T; Yang D; Li M
    Chin Med J (Engl); 2002 Sep; 115(9):1296-300. PubMed ID: 12411098
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chronic myelogenous leukemia: molecular and cellular aspects.
    Pasternak G; Hochhaus A; Schultheis B; Hehlmann R
    J Cancer Res Clin Oncol; 1998; 124(12):643-60. PubMed ID: 9879825
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Circulating myeloid dendritic cell directly isolated from patients with chronic myelogenous leukemia are functional and carry the bcr-abl translocation.
    Orsini E; Calabrese E; Maggio R; Pasquale A; Nanni M; Trasarti S; Tafuri A; Guarini A; Foa R
    Leuk Res; 2006 Jul; 30(7):785-94. PubMed ID: 16527350
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Induction of leukemia-specific cytotoxic response by cross-presentation of late-apoptotic leukemic blasts by autologous dendritic cells of nonleukemic origin.
    Spisek R; Chevallier P; Morineau N; Milpied N; Avet-Loiseau H; Harousseau JL; Meflah K; Gregoire M
    Cancer Res; 2002 May; 62(10):2861-8. PubMed ID: 12019165
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Generation of dendritic cells expressing bcr-abl from CD34-positive chronic myeloid leukemia precursor cells.
    Smit WM; Rijnbeek M; van Bergen CA; de Paus RA; Vervenne HA; van de Keur M; Willemze R; Falkenburg JH
    Hum Immunol; 1997 Apr; 53(2):216-23. PubMed ID: 9129981
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical grade expansion of CD45RA, CD45RO, and CD62L-positive T-cell lines from HLA-compatible donors: high cytotoxic potential against AML and ALL cells.
    Barbui AM; Borleri G; Conti E; Ciocca A; Salvi A; Micò C; Introna M; Rambaldi A
    Exp Hematol; 2006 Apr; 34(4):475-85. PubMed ID: 16569594
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunologic evaluation of peptides derived from BCR/ABL-out-of-frame fusion protein in HLA A2.1 transgenic mice.
    Casnici C; Volpe G; Crotta K; Lattuada D; Saglio G; Marelli O
    J Immunother; 2012 May; 35(4):321-8. PubMed ID: 22495389
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Specific anti-leukemic cell effect mediated by dendritic cells pulsed with chronic myelogenous leukemia lysate antigen in vitro].
    Zhu HH; Xu KL; Pan XY; Liu JQ; Chen FX; Huang YH
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2003 Jun; 11(3):278-81. PubMed ID: 12844413
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The quality and quantity of leukemia-derived dendritic cells from patients with acute myeloid leukemia and myelodysplastic syndrome are a predictive factor for the lytic potential of dendritic cells-primed leukemia-specific T cells.
    Grabrucker C; Liepert A; Dreyig J; Kremser A; Kroell T; Freudenreich M; Schmid C; Schweiger C; Tischer J; Kolb HJ; Schmetzer H
    J Immunother; 2010 Jun; 33(5):523-37. PubMed ID: 20463595
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The generation of immunocompetent dendritic cells from CD34+ acute myeloid or lymphoid leukemia cells.
    Tsuchiya T; Hagihara M; Shimakura Y; Ueda Y; Gansuvd B; Munkhbat B; Inoue H; Tazume K; Kato S; Hotta T
    Int J Hematol; 2002 Jan; 75(1):55-62. PubMed ID: 11843292
    [TBL] [Abstract][Full Text] [Related]  

  • 17. BCR-ABL-specific CD4
    Ueda N; Zhang R; Tatsumi M; Liu TY; Kitayama S; Yasui Y; Sugai S; Iwama T; Senju S; Okada S; Nakatsura T; Kuzushima K; Kiyoi H; Naoe T; Kaneko S; Uemura Y
    Cell Mol Immunol; 2018 Jan; 15(1):15-26. PubMed ID: 27181332
    [TBL] [Abstract][Full Text] [Related]  

  • 18. BCR/ABL promotes dendritic cell-mediated natural killer cell activation.
    Terme M; Borg C; Guilhot F; Masurier C; Flament C; Wagner EF; Caillat-Zucman S; Bernheim A; Turhan AG; Caignard A; Zitvogel L
    Cancer Res; 2005 Jul; 65(14):6409-17. PubMed ID: 16024645
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A CD4+ T cell clone selected from a CML patient after donor lymphocyte infusion recognizes BCR-ABL breakpoint peptides but not tumor cells.
    Zorn E; Orsini E; Wu CJ; Stein B; Chillemi A; Canning C; Alyea EP; Soiffer RJ; Ritz J
    Transplantation; 2001 Apr; 71(8):1131-7. PubMed ID: 11374415
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Leukemia cell lines: in vitro models for the study of Philadelphia chromosome-positive leukemia.
    Drexler HG; MacLeod RA; Uphoff CC
    Leuk Res; 1999 Mar; 23(3):207-15. PubMed ID: 10071072
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.